Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) saw unusually-strong trading volume on Friday . Approximately 633,416 shares changed hands during trading, an increase of 56% from the previous session’s volume of 405,334 shares.The stock last traded at $7.52 and had previously closed at $7.34.

Several equities analysts have recently weighed in on PETX shares. Jefferies Group reissued a “buy” rating and set a $12.00 price target on shares of Aratana Therapeutics in a report on Saturday, April 2nd. Credit Suisse Group AG reissued a “buy” rating on shares of Aratana Therapeutics in a report on Saturday, April 2nd. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a report on Tuesday, April 26th. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Thursday, July 7th. Finally, Lake Street Capital reissued a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a report on Sunday, July 17th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Aratana Therapeutics currently has an average rating of “Buy” and a consensus price target of $11.66.

The company has a 50 day moving average of $6.55 and a 200-day moving average of $5.40. The company’s market capitalization is $268.28 million.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.10. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. During the same quarter in the prior year, the company earned ($0.26) earnings per share. The company’s revenue was up 6.3% on a year-over-year basis. Equities research analysts anticipate that Aratana Therapeutics Inc. will post ($1.02) earnings per share for the current fiscal year.

In other news, insider Julia A. Stephanus sold 30,000 shares of Aratana Therapeutics stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the completion of the sale, the insider now directly owns 127,503 shares in the company, valued at $796,893.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ernst Heinen sold 15,000 shares of Aratana Therapeutics stock in a transaction on Friday, June 10th. The stock was sold at an average price of $6.72, for a total transaction of $100,800.00. Following the sale, the insider now owns 125,494 shares of the company’s stock, valued at $843,319.68. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Aratana Therapeutics stock. Jennison Associates boosted its position in shares of Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned about 11.84% of Aratana Therapeutics worth $35,077,000 at the end of the most recent reporting period.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.